Moderna Inc (NASDAQ:MRNA) will report second quarter earnings tomorrow before the open. There is a conference call scheduled for 8:00 ET.
Q2 Capital IQ consensus calls for EPS of $5.86 vs. ($0.31) last year on revenue of $4.233 billion versus $66.3 million last year. The company typically does not provide EPS or revenue guidance.
The first area of interest will be the company’s COVID-19 vaccine. The company recently Increased 2021 supply forecast to between 800 million and 1 billion doses; making additional investments to increase global supply for COVID-19 vaccine to up to 3 billion doses in 2022. The CDC reported that nearly 140 million doses of MRNA’s COVID-19 vaccine has been administered in US. The company may also give some more information on potential booster shots and when shots will be available for kids during the conference call.
The company beat on EPS two of the last four quarters while it beat on revenues three out of the last four quarters.
MRNA has a $155 billion valuation and trades at ~13x FY21 EPS estimates which is a premium to peer Pfizer (PFE). Based on the weekly MRNA Weekly Aug06 $386.00 straddle, the options market is currently pricing in a move of ~6% in either direction by weekly expiration (Friday).
